anti cd47 antibody (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
95
Structured Review
Bio X Cell
anti cd47 antibody
Anti Cd47 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+antibody/InVivoMAb+anti-mouse+human+rat+CD47/pm42901146-411-48-52
Average 95 stars, based on 48 article reviews
Anti Cd47 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+antibody/InVivoMAb+anti-mouse+human+rat+CD47/pm42901146-411-48-52
Average 95 stars, based on 48 article reviews
anti cd47 antibody - by Bioz Stars,
2026-11
95/100 stars
Images
Related Articles
Control:Article Title: Imiquimod enhances anti-tumor effects of CD47 targeting in oral squamous cell carcinoma. Article Snippet: Oral squamous cell carcinoma (OSCC) represents the most prevalent malignancy within oral cavity, which accounts for over 90% of all oral cancers [1, 2].. OSCC has become rising global burden, with an alarming fatality rate and 380,000 new cases annually [3].. Despite advancements in therapeutic interventions, the 5-year survival rate stays stagnant at roughly 50% for OSCC, highlighting the urgent need for innovative therapeutic strategies [4]. Article Title: CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target. Article Snippet: .. For in vitro phagocytosis assays, primary intestinal fibroblasts were stimulated with TGF-β where indicated, labeled with CFSE (5 μM; eBioscience, 65–0850-84) for 20 min at room temperature, washed, and co-cultured with BMDMs for 24 h. For antibody-blockade assays, TGF-β-stimulated CFSE-labeled fibroblast-BMDM cultures were treated for 30 min with Incubation:Article Title: Imiquimod enhances anti-tumor effects of CD47 targeting in oral squamous cell carcinoma. Article Snippet: Oral squamous cell carcinoma (OSCC) represents the most prevalent malignancy within oral cavity, which accounts for over 90% of all oral cancers [1, 2].. OSCC has become rising global burden, with an alarming fatality rate and 380,000 new cases annually [3].. Despite advancements in therapeutic interventions, the 5-year survival rate stays stagnant at roughly 50% for OSCC, highlighting the urgent need for innovative therapeutic strategies [4]. Flow Cytometry:Article Title: Imiquimod enhances anti-tumor effects of CD47 targeting in oral squamous cell carcinoma. Article Snippet: Oral squamous cell carcinoma (OSCC) represents the most prevalent malignancy within oral cavity, which accounts for over 90% of all oral cancers [1, 2].. OSCC has become rising global burden, with an alarming fatality rate and 380,000 new cases annually [3].. Despite advancements in therapeutic interventions, the 5-year survival rate stays stagnant at roughly 50% for OSCC, highlighting the urgent need for innovative therapeutic strategies [4]. Analysis:Article Title: Imiquimod enhances anti-tumor effects of CD47 targeting in oral squamous cell carcinoma. Article Snippet: Oral squamous cell carcinoma (OSCC) represents the most prevalent malignancy within oral cavity, which accounts for over 90% of all oral cancers [1, 2].. OSCC has become rising global burden, with an alarming fatality rate and 380,000 new cases annually [3].. Despite advancements in therapeutic interventions, the 5-year survival rate stays stagnant at roughly 50% for OSCC, highlighting the urgent need for innovative therapeutic strategies [4]. In Vitro:Article Title: CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target. Article Snippet: .. For in vitro phagocytosis assays, primary intestinal fibroblasts were stimulated with TGF-β where indicated, labeled with CFSE (5 μM; eBioscience, 65–0850-84) for 20 min at room temperature, washed, and co-cultured with BMDMs for 24 h. For antibody-blockade assays, TGF-β-stimulated CFSE-labeled fibroblast-BMDM cultures were treated for 30 min with Labeling:Article Title: CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target. Article Snippet: .. For in vitro phagocytosis assays, primary intestinal fibroblasts were stimulated with TGF-β where indicated, labeled with CFSE (5 μM; eBioscience, 65–0850-84) for 20 min at room temperature, washed, and co-cultured with BMDMs for 24 h. For antibody-blockade assays, TGF-β-stimulated CFSE-labeled fibroblast-BMDM cultures were treated for 30 min with Injection:Article Title: Methods and compositions for the treatment of cancer Article Snippet: .. For Blocking Assay:Article Title: Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer Article Snippet: Subsequently, the cellular uptake was assessed using a CytoFLEX flow cytometer (Beckman Coulter, USA). .. For blocking CD47, 4T1 cells were pre‐treated with Membrane:Article Title: Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer Article Snippet: Subsequently, the cellular uptake was assessed using a CytoFLEX flow cytometer (Beckman Coulter, USA). .. For blocking CD47, 4T1 cells were pre‐treated with Mouse Assay:Article Title: FACS-based genome-wide CRISPR screening platform identifies modulators of CD47 Article Snippet: .. Mice with palpable tumors of similar size on day 5 were treated with In Vivo:Article Title: FACS-based genome-wide CRISPR screening platform identifies modulators of CD47 Article Snippet: .. Mice with palpable tumors of similar size on day 5 were treated with |
